Endogena finalises enrolment for retinitis pigmentosa trial
PharmaTimes
MAY 4, 2023
The treatment is a small molecule that activates endogenous retinal stem and progenitor cells
PharmaTimes
MAY 4, 2023
The treatment is a small molecule that activates endogenous retinal stem and progenitor cells
MedCity News
APRIL 30, 2023
A new study found that ChatGPT might actually be quite successful in providing high-quality answers to patient questions during an era in which doctors and nurses are too busy to do so. The research evaluated two sets of answers to patient inquiries — one written by physicians, the other by ChatGPT. A panel of healthcare professionals determined that ChatGPT’s answers were significantly more detailed and empathetic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
MAY 1, 2023
The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.
Fierce Pharma
MAY 3, 2023
ImmunoGen touts 'home run' as ovarian cancer drug Elahere extends lives in landmark trial win aliu Wed, 05/03/2023 - 14:50
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Dominic Tyer
MAY 5, 2023
Pharma has an opportunity to make more effective - and wider - use of social media, but companies are not currently meeting HCP expectations
MedCity News
MAY 3, 2023
The Drug Enforcement Administration received 38,000 comments on its proposed rule that would roll back Covid-19 flexibilities for the prescribing of controlled substances via telemedicine. In response, the DEA chose to temporarily extend the flexibilities, a decision telehealth companies like Bicycle Health and Mindbloom are in support of.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Fierce Pharma
MAY 2, 2023
Pfizer pulls off Q1 surprise with strong sales even as COVID vaccine demand plummets kdunleavy Tue, 05/02/2023 - 09:27
European Pharmaceutical Review
MAY 3, 2023
The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Scientists at Northwestern Medicine in the US showed that opening the BBB led to an approximately four- to six-fold increase in drug concentrations in the human brain, results from the study found.
MedCity News
MAY 3, 2023
In an interview, Rob Bressler, general manager for Teladoc Health’s virtual primary care solution Primary360, talked about the company’s shift from telehealth for urgent care to whole person care.
Medgadget
MAY 3, 2023
Researchers at MIT have developed a printer that can create large numbers of microneedle patch-style vaccines in places where they are needed quickly. Moreover, the printed patches can deliver thermostable mRNA vaccines, whereby the mRNA therapeutic is encapsulated in lipid nanoparticles before printing to enhance its shelf-life at room temperature and avoid the need for cold storage and transport.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
MAY 2, 2023
GSK staffers kick off series of strikes in UK for the first time in drugmaker's history aliu Tue, 05/02/2023 - 14:22
Pharmaceutical Technology
MAY 1, 2023
Astellas Pharma has entered into a definitive agreement to buy US-based biopharmaceutical company Iveric bio, in a deal valued at nearly $5.9bn. Under the deal terms, the company, through Astellas US Holding’s wholly owned subsidiary Berry Merger Sub, will acquire all the outstanding Iveric Bio shares for $40.00 in cash for each share. Both the companies’ Boards of Directors have unanimously approved the deal.
MedCity News
MAY 4, 2023
Oncology Ventures recently announced investments in three cancer startups — VivorCare, Gabbi and Health Universe. The fund’s founding partner said each company demonstrated an ability to tackle a specific problem within the cancer care space, such as enabling earlier breast cancer diagnoses and providing personalized care plans for cancer survivors.
Medgadget
MAY 1, 2023
Researchers at Northwestern University and the University of Texas at Austin have developed a thin and flexible graphene “tattoo” that can be affixed to the outside of the heart, and which can monitor heart rhythms and apply corrective electrical impulses to treat arrhythmias. The patch is optically clear, allowing the researchers to also use light to monitor and stimulate the heart.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Fierce Pharma
MAY 4, 2023
Moderna warns of severe sales slowdown in Q2, takes $378M charge amid lull in vaccinations aliu Thu, 05/04/2023 - 10:02
Pharmaceutical Technology
MAY 4, 2023
Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. Gene therapy clients will gain access to coordinated scientific expertise, drug development services and AAV manufacturing capabilities, advancing the development of new gene therapies.
MedCity News
MAY 1, 2023
With obesity, diabetes, and heart disease rapidly growing among communities of color, we need to do everything we can to help people sustain healthy eating habits. It’ll take more nuance than a Westernized one-size-fits-all diet.
PharmaVoice
MAY 2, 2023
What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.
Advertiser: ZoomInfo
Shifting to an account-based marketing (ABM) strategy can be both exciting and challenging. Well-implemented ABM motions build engagement with high-value accounts and drive impactful campaigns that resonate with your audience. But where do you begin, and how do you progress from crawling to running? Watch now as Demand Gen experts delve into the essentials of each stage of the ABM process.
Fierce Pharma
MAY 4, 2023
J&J's consumer group Kenvue set for $41B IPO, the largest US market debut in more than a year esagonowsky Thu, 05/04/2023 - 09:58
Medgadget
MAY 1, 2023
Researchers at Linköping University in Sweden created a wound dressing that can provide a visual indication if the underlying wound is infected. Chronic wounds are difficult to manage, and presently healthcare staff must remove the dressing regularly to check if an infection is developing. However, this can disrupt the wound by damaging the scab, impairing healing, and may even introduce pathogens in the process.
MedCity News
MAY 5, 2023
Absent the ability to bolster their ranks with more clinicians, what rural health centers need first and foremost to shift to value are technologies that amplify their clinical capacity without further burdening and burning out their core staff.
Pharmaceutical Technology
MAY 4, 2023
Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for KALYDECO (ivacaftor) to treat children with cystic fibrosis (CF) aged between one and four months. The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results.
Advertiser: ZoomInfo
One of the biggest challenges for any B2B marketer is understanding your prospects’ next move — who is most likely to buy and when. Without these insights, marketing campaigns can feel more like guesswork, with high investment and little return. We’re here to tell you there’s a better way. By tracking buyers’ digital footprints and online activity, such as website visits, product reviews, and spikes in content consumption, you can engage prospects with a message that really resonates.
Fierce Pharma
MAY 2, 2023
Poland takes its COVID-19 vaccine fight to Pfizer's shareholders, urging the company to be a good corporate citizen zbecker Tue, 05/02/2023 - 16:34
Evolve Your Success
MAY 2, 2023
Your resume is the key that unlocks the door to your dream job. Invest in it wisely, and let it showcase your unique blend of skills, experience, and potential. With the right words, format, and strategy, you can open doors you never thought possible. In this episode, Samuel Adeyinka sits down with Cathy Lanzalaco. Cathy, who started as a nurse and later transitioned to HR, shares her journey of starting her own business and how she helps people land jobs and build their careers through effectiv
MedCity News
MAY 1, 2023
New CVS Health data found that while 42% of respondents are concerned about their mental health, only 12% are seeing a mental health professional, such as a psychiatrist, psychologist, psychotherapist or wellbeing therapist. Younger respondents are especially struggling: 60% of those aged 18 to 32 years old are concerned about their mental health.
Pharmaceutical Technology
MAY 3, 2023
Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year. First generics are the first opportunity manufacturers have to market new generic drug products in the US. In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma,
Advertiser: ZoomInfo
In this eBook, we’ll run through real-world examples that show how RevOps teams can benefit from modern solutions for the access, management, and activation of their GTM data. Whether you need to improve lead response times, boost adoption of core tools, improve lead qualification, or target and automate your GTM motions, you’ll find examples of how revenue teams are solving some of the toughest problems in modern business.
Fierce Pharma
MAY 1, 2023
Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy kdunleavy Mon, 05/01/2023 - 07:35
Legacy MEDSearch
MAY 3, 2023
ORLANDO, Fla., May 3, 2023 – Legacy MEDSearch has been named to the Forbes Best Executive Recruitment Firms and Forbes Best Professional Recruiting Firms out of over 25,000 recruitment and staffing firms in the United States, its fifth consecutive mention since 2019. Forbes Best Recruiting Firms lists are based on votes by industry professionals, who have directly worked with recruiting firms and rankings are earned based on merit.
MedCity News
MAY 5, 2023
Formus Labs, a New Zealand-based medical technology startup, has received 510(k) clearance from the FDA for Formus Hip, its fully automated 3D software for hip replacement preoperative planning. The company hopes to start piloting the product at healthcare sites across the U.S. in the next few months.
Pharmaceutical Technology
MAY 2, 2023
The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application submitted by Bristol Myers Squibb for Reblozyl (luspatercept-aamt) as a first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS). The regulatory body has also granted priority review to the application and set 28 August 2023 as a target date for the prescription drug user fee act (PDUFA).
Advertiser: ZoomInfo
Consolidating your tech stack is an effective cost-saving measure that drives GTM efficiency and adds value to your enterprise. With a cohesive, integrated tech stack, your revenue teams can deliver an excellent customer experience that sets you up to win faster than your competitors.
Let's personalize your content